Search - tctmd.com

Displaying 121 - 140 of 286

Sort: Relevancy | Date

Presentation TCT 2018

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

Presenter: John A. Bittl, C. Michael Gibson, Dimitrios Alexopoulos

September 23, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

Presentation TCT 2018

TROPICAL-ACS: Platelet Reactivity and Clinical Outcomes in Acute Coronary Syndrome Patients Treated With Prasugrel and Clopidogrel

Presenter: Jonathan M. Hill, E. Magnus Ohman, Dániel Aradi

September 22, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Yael L. Maxwell

June 08, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Daily News

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Michael O'Riordan

May 21, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Todd Neale

April 27, 2018

News Daily News

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Yael L. Maxwell

April 04, 2018

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

News Conference News ACC 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

Caitlin E. Cox

March 11, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Multivessel PCI Improves Outcomes in STEMI Patients With Cardiogenic Shock: Korean Registry

Caitlin E. Cox

February 23, 2018

News Daily News

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Yael L. Maxwell

January 04, 2018

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

L.A. McKeown

January 02, 2018

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

Advertisement

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

TROPICAL-ACS: Platelet Reactivity and Clinical Outcomes in Acute Coronary Syndrome Patients Treated With Prasugrel and Clopidogrel

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Multivessel PCI Improves Outcomes in STEMI Patients With Cardiogenic Shock: Korean Registry

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content